Interim Report Q1, 2023
Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout“In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this clinically relevant endpoint of kidney filtration capability represents a crowning achievement after well over a decade of pioneering work in IgA nephropathy. Nefecon, commercially available in the US and Europe under the brand name TARPEYO[®] and Kinpeygo[®] respectively, seems to be disease modifying, having shown both immediate and enduring